Cellectar Biosciences
CLRB
32 hedge funds and large institutions have $1.63M invested in Cellectar Biosciences in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 6 closing their positions.
200% more call options, than puts
Call options by funds: $18K | Put options by funds: $6K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
7% more capital invested
Capital invested by funds: $1.52M → $1.63M (+$104K)
7% more funds holding
Funds holding: 30 → 32 (+2)
0.04% less ownership
Funds ownership: 0.41% → 0.38% (-0.04%)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$164K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$104K |
| 3 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$57K |
| 4 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$52.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$165K |
| 2 |
ACM
Altium Capital Management
New York
|
-$64.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$62.3K |
| 4 |
JP Morgan Chase
New York
|
-$55K |
| 5 |
Morgan Stanley
New York
|
-$49.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $293 | -$543 | -60 | -66% |
|
|
SS
27
SBI Securities
Tokyo,
Japan
| $126 | – | – | – |
|
|
28
Bank of America
Charlotte,
North Carolina
| $109 | -$62.3K | -6,881 | -100% |
|
29
US Bancorp
Minneapolis,
Minnesota
| $32 | -$91 | -10 | -77% |
|
|
30
JP Morgan Chase
New York
| $24 | -$55K | -6,077 | -100% |
|
|
HI
31
Harbour Investments
Madison,
Wisconsin
| $16 | +$9 | +1 | +100% |
|
|
AWM
32
AllSquare Wealth Management
Albany,
New York
| $6 | – | – | – |
|
|
ACM
33
Altium Capital Management
New York
| – | -$64.3K | -7,167 | Closed |
|
|
TSS
34
Two Sigma Securities
New York
| – | -$15.5K | -1,732 | Closed |
|
35
BNP Paribas Financial Markets
Paris,
France
| – | -$5.03K | -561 | Closed |
|
|
BL
36
BFSG LLC
Irvine,
California
| – | -$299 | -33 | Closed |
|
37
Citigroup
New York
| – | -$197 | -22 | Closed |
|
|
EFP
38
EnRich Financial Partners
Madison,
Wisconsin
| – | -$30 | -3 | Closed |
|
CLRB Hedge Fund Activity: Q1 2025 in Review
32 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2025, worth a combined $1.63M — up 6.8% from $1.52M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CLRB positions and 6 closed out — a net gain of 2 holders — while 7 added to existing stakes and 10 trimmed.
The largest buyer was UBS Group, adding an estimated $164K. The largest seller was ADAR1 Capital Management, cutting an estimated $165K.
- 32 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2025, up from 30 in Q4 2024.
- Funds reported $1.63M of Cellectar Biosciences stock for Q1 2025, up 6.8% quarter-over-quarter.
- 8 funds opened new Cellectar Biosciences positions in Q1 2025 and 6 closed out, a net change of +2 holders.
- The largest Cellectar Biosciences buyer in Q1 2025 was UBS Group, an estimated $164K added.
- The largest Cellectar Biosciences seller in Q1 2025 was ADAR1 Capital Management, an estimated $165K sold.
Based on aggregated 13F filings for Q1 2025.